SCHEMBL4270804

SCHEMBL4270804

CCOC(=O)CC(=O)c1ccc(-c2ccccc2)cc1

nearest known ligand 0.61

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 5/20 0.61
SMN1; SMN2 Q16637 3/20 0.61
L3MBTL1 Q9Y468 2/20 0.61
HPGD P15428 1/20 0.57
ERCC5 P28715 1/20 0.57
FEN1 P39748 1/20 0.57
HAO1 Q9UJM8 1/20 0.57
ALDH1A1 P00352 5/20 0.53
KDM4E B2RXH2 3/20 0.53
AGTR1 P30556 1/20 0.53
MEN1 O00255 4/20 0.51
KMT2A Q03164 4/20 0.51
RAB9A P51151 4/20 0.51
NPC1 O15118 3/20 0.51
PTPN1 P18031 1/20 0.51
GSK3B P49841 1/20 0.51
USP2 O75604 1/20 0.51
LMNA P02545 2/20 0.50
CYP1A2 P05177 2/20 0.50
POLB P06746 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL124577 0.90 KMT2A (0.59) MAPTSMN1; SMN2L3MBTL1HPGDERCC5
SCHEMBL23149606 0.90 ERCC5 (0.57) MAPTSMN1; SMN2L3MBTL1HPGDERCC5
SCHEMBL17433641 0.88 KMT2A (0.57) MAPTSMN1; SMN2L3MBTL1HPGDERCC5
SCHEMBL31439645 0.88 KMT2A (0.57) MAPTSMN1; SMN2L3MBTL1HPGDERCC5
SCHEMBL28792148 0.88 KMT2A (0.57) MAPTSMN1; SMN2L3MBTL1HPGDERCC5
SCHEMBL6753757 0.88 KMT2A (0.57) MAPTSMN1; SMN2L3MBTL1HPGDERCC5
SCHEMBL17433632 0.88 KMT2A (0.57) MAPTSMN1; SMN2L3MBTL1HPGDERCC5
SCHEMBL17433663 0.88 KMT2A (0.57) MAPTSMN1; SMN2L3MBTL1HPGDERCC5
SCHEMBL17433560 0.88 KMT2A (0.57) MAPTSMN1; SMN2L3MBTL1HPGDERCC5
SCHEMBL28048832 0.88 KMT2A (0.57) MAPTSMN1; SMN2L3MBTL1HPGDERCC5

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7605176-B2 β-ketoamide compounds with MCH antagonistic activity BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2009-10-20 US disclosed
US-7605176-B2 β-ketoamide compounds with MCH antagonistic activity BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2009-10-20 US disclosed
US-7605176-B2 β-ketoamide compounds with MCH antagonistic activity BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2009-10-20 US disclosed
EP-1730130-A1 BETA-KETOAMIDE COMPOUNDS HAVING AN MCH-ANTAGONISTIC EFFECT AND MEDICAMENTS CONTAINING SAID COMPOUNDS Boehringer Ingelheim International GmbH (DE) 2006-12-13 EP disclosed
US-20050245500-A1 Beta-ketoamide compounds with MCH antagonistic activity BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2005-11-03 US disclosed
WO-2005085221-A1 BETA-KETOAMIDE COMPOUNDS HAVING AN MCH-ANTAGONISTIC EFFECT AND MEDICAMENTS CONTAINING SAID COMPOUNDS BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2005-09-15 WO disclosed
US-3980795-A Pyrazolidinones and a process for their preparation MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DT) 1976-09-14 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050245500-A1 Beta-ketoamide compounds with MCH antagonistic activity MCHR2, MCHR1, NPY1R MAPT 4030/4885SMN1; SMN2 2654/4885L3MBTL1 929/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.